WO1996012508A3 - Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy - Google Patents

Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy Download PDF

Info

Publication number
WO1996012508A3
WO1996012508A3 PCT/CA1995/000593 CA9500593W WO9612508A3 WO 1996012508 A3 WO1996012508 A3 WO 1996012508A3 CA 9500593 W CA9500593 W CA 9500593W WO 9612508 A3 WO9612508 A3 WO 9612508A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
product
protein
those
foreign gene
Prior art date
Application number
PCT/CA1995/000593
Other languages
French (fr)
Other versions
WO1996012508A2 (en
Inventor
Edward E Knaus
Leonard I Wiebe
Kevin Morin
Original Assignee
Univ Alberta
Edward E Knaus
Wiebbe Leonard I
Kevin Morin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta, Edward E Knaus, Wiebbe Leonard I, Kevin Morin filed Critical Univ Alberta
Priority to EP95934027A priority Critical patent/EP0784489A2/en
Priority to JP8513558A priority patent/JPH10510046A/en
Priority to AU36486/95A priority patent/AU715811B2/en
Publication of WO1996012508A2 publication Critical patent/WO1996012508A2/en
Publication of WO1996012508A3 publication Critical patent/WO1996012508A3/en
Priority to US09/855,176 priority patent/US20020025296A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Diagnostic, radiotherapy, and chemotherapy methods which may be used in conjunction with gene therapy techniques, and the use of certain compounds in performing these methods. The methods are applicable to populations of cells into which a foreign gene has been transferred, which foreign gene expresses a protein which preferably is not naturally occuring within the cells. A compound is selected which will interact selectively with the protein expressed by the foreign gene to produce a product which is trapped within the cells, is cytotoxix or cytostatic to the cells, or both, depending upon whether the compound is being used for diagnostic purposes or for radiotherapy or chemotherapy purposes. In the case of diagnostic applications, trapping of the product, which is labelled, permits the product to accumulate in those of the cells in which the protein has been expressed by the foreign gene, thus facilitating detection of the labelled product in those cells. In the case of radiotherapy applications, trapping of the product, which is radioactive as a result of the compound being radiolabelled, permits the product to accumulate in those of the cells in which the protein has been expressed by the foreign gene, thus facilitating radiotherapeutic effects directed specifically at those cells. In the case of chemotherapy applications, interaction of the protein with the compound has either a cytotoxic or a cytostatic effect on the cells, which is enhanced if the product is trapped within those of the cells in which the protein has been expressed.
PCT/CA1995/000593 1994-10-21 1995-10-20 Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy WO1996012508A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95934027A EP0784489A2 (en) 1994-10-21 1995-10-20 Composition use of nucleoside analogues and gene transfection for tissue imaging and therapy
JP8513558A JPH10510046A (en) 1994-10-21 1995-10-20 Use of nucleoside analog compositions for tissue imaging and therapy and gene transfection
AU36486/95A AU715811B2 (en) 1994-10-21 1995-10-20 Composition use of nucleoside analogues and gene transfection for tissue imaging and therapy
US09/855,176 US20020025296A1 (en) 1994-10-21 2001-05-14 Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9421223.0 1994-10-21
GB9421223A GB9421223D0 (en) 1994-10-21 1994-10-21 Tissue imaging in gene therapy

Publications (2)

Publication Number Publication Date
WO1996012508A2 WO1996012508A2 (en) 1996-05-02
WO1996012508A3 true WO1996012508A3 (en) 1996-07-11

Family

ID=10763176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000593 WO1996012508A2 (en) 1994-10-21 1995-10-20 Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy

Country Status (6)

Country Link
EP (1) EP0784489A2 (en)
JP (1) JPH10510046A (en)
AU (1) AU715811B2 (en)
CA (1) CA2202891A1 (en)
GB (1) GB9421223D0 (en)
WO (1) WO1996012508A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1160499A (en) * 1997-08-22 1999-03-02 Hiroshi Maeda Antitumor agent
WO2000025830A2 (en) * 1998-11-03 2000-05-11 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin Biomimetic elements containing iodine and/or tellurium, the production thereof and their use
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BALZARINI J ET AL: "Comparative cytostatic activity of different antiherpetic drugs against herpes simplex virus thymidine kinase gene-transfected tumor cells.", MOL PHARMACOL, JUN 1994, VOL. 45, NO. 6, PAGE(S) 1253-8, XP000563719 *
BALZARINI J ET AL: "Highly selective cytostatic activity of (E)-5-(2-bromovinyl)-2'- deoxyuridine derivatives for murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 thymidine kinase gene.", MOL PHARMACOL, DEC 1985, VOL. 28, NO. 6, PAGE(S) 581-7, XP000563717 *
BALZARINI J ET AL: "Thymidylate synthase is the principal target enzyme for the cytostatic activity of (E)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene.", MOL PHARMACOL, SEP 1987, VOL. 32, NO. 3, PAGE(S) 410-6, XP000563715 *
DE CLERCQ, ERIK ET AL: "Metabolism of the carbocyclic analog of (E)-5-(2-iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells. Incorporation of C-IVDU into DNA", J. BIOL. CHEM., 1985, VOL. 260, NO. 19, PAGES 10621-8, XP000562815 *
DOUGAN H ET AL: "NO-CARRIER-ADDED NCA 1-BETA-D ARABINOFURANOSYL-5E-2- RADIOIODOVINYL URACIL IVARAU PROBES FOR THE DETECTION OF HERPES SIMPLEX VIRUS HSV-SPECIFIED THYMIDINE KINASE TK IN-VIVO AND IN-VITRO", 40TH ANNUAL MEETING OF THE SOCIETY OF NUCLEAR MEDICINE, TORONTO, ONTARIO, CANADA, JUNE 8-11, 1993. &: J NUCL MED, 1993, VOL. 34, NO. 5 SUPPL., PAGE(S) 235P. *
GILL MJ ET AL: "Quantitative uptake studies of 131I-labeled (E)-5-(2- iodovinyl)-2'-deoxyuridine in herpes simplex virus-infected cells in vitro.", ANTIMICROB AGENTS CHEMOTHER, APR 1984, VOL. 25, NO. 4, PAGE(S) 476-8, XP000562822 *
KUMAR, RAKESH ET AL: "Synthesis of brain-targeted 5-iodo-, 5-vinyl-, and (E)-5-(2-iodovinyl)-2'-deoxyuridine coupled to a dihydropyridine.dblharw. pyridinium salt redox chemical delivery system", J. HETEROCYCL. CHEM., 1991, 711-15 *
MORIN K W ET AL: "Synthesis of brain-targeted 1-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)-(E)-5-(2-iodovinyl) uracil coupled to a dihydropyridine dblarw pyridinium salt redox chemical-delivery system", CARBOHYDRATE RESEARCH, 1993, VOL. 249, NO. 1, PAGE(S) 109-116. *
ROBINS MJ ET AL: "Nucleic acid related compounds. 65. New syntheses of 1-(beta-D-arabinofuranosyl)-5(E)-(2-iodovinyl)uracil (IVAra U) from vinylsilane precursors. Radioiodine uptake as a marker for thymidine kinase positive herpes viral infections.", J MED CHEM, JUL 1991, VOL. 34, NO. 7, PAGE(S) 2275-80 *
YOKOTA T ET AL: "Incorporation of (E)-5-(2-iodovinyl)-2'-deoxyuridine into deoxyribonucleic acids of varicella-zoster virus (TK+ and TK- strains)-infected cells.", MOL PHARMACOL, MAY 1987, VOL. 31, NO. 5, PAGE(S) 493-9, XP000563716 *

Also Published As

Publication number Publication date
CA2202891A1 (en) 1996-05-02
AU715811B2 (en) 2000-02-10
AU3648695A (en) 1996-05-15
JPH10510046A (en) 1998-09-29
EP0784489A2 (en) 1997-07-23
WO1996012508A2 (en) 1996-05-02
GB9421223D0 (en) 1994-12-07

Similar Documents

Publication Publication Date Title
MXPA02000192A (en) Compositions and methods for the therapy and diagnosis of lung cancer.
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO1999004265A8 (en) Cancer associated nucleic acids and polypeptides
EP0726941A4 (en) METHODS FOR -i(EX VIVO) THERAPY USING PEPTIDE-LOADED ANTIGEN PRESENTING CELLS FOR THE ACTIVATION OF CTL
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
GB2276623A (en) Cytotoxic drug therapy
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
EP0979656A3 (en) Composition containing radioisotopes immobilised on solid particles, and its use in brachytherapy
WO1998039034A3 (en) Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
WO1996012508A3 (en) Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
ES8704082A1 (en) Tumour therapeutic agent and process for its preparation.
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
WO2002000174A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
Gottlieb The antigen-RNA complex of macrophages
WO2002002623A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2202891

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2202891

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 293918

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995934027

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995934027

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995934027

Country of ref document: EP